| Popis: |
Objective A systematic review of the clinical efficacy of irbesartan combined therapy in the treatment of hypertension and erectile function in men. Methods Use computer to search databases such as CNKI, CBM, Weipu, Wanfang, Embase, PubMed and Cochrane, and find all the randomized controlled trials (RCT) about the effect of irbesartan combination on the sexual function of male hypertensive patients. After screening according to the inclusion and exclusion criteria, the Cochrane risk of bias tool was used to evaluate the methodological quality of the included studies,and use Review Manager 5.2 software for system evaluation. Results Finally, 11 eligible RCTs with a total of 1350 participants were screened, and a meta-analysis was completed based on these RCTs. The results of Meta analysis showed that compared with other combination medication groups,Irbesartan combination group was better than other medication groups in the incidence of ED (OR = 0.57, 95％CI=(0.37,0.86), P=0.008), serum T (MD = 1.27, 95％CI=(0.69,1.84), PP=0.002). There was no statistical difference in the total effective rate of lowering blood pressure, the rate of lowering blood pressure, and erectile function. None of the included RCTs mentioned serious adverse events. Conclusions The combination of irbesartan in the treatment of male hypertensive patients with sexual dysfunction was better than other combination groups, and there were no serious adverse reactions during the treatment. However, due to the generally low quality of the included studies, so a larger sample, multi-center, high-quality clinical trial was needed to prove it. |
